ArticleCureus2026
Yamaguchi Syndrome: A Case of Apical Hypertrophic Cardiomyopathy in a Patient From West Africa.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy. The apical variant, also known as Yamaguchi syndrome, is a rare condition that is reportedly more prevalent in Asian populations. It is characterized by hypertrophy predominantly limited to the left ventricular apex, with a classic "ace of spades" shaped left ventricular cavity. We present a 61-year-old male of West African descent with a chest pain syndrome and deep inverted precordial T-waves on 12-lead electrocardiography. Two-dimensional echocardiography demonstrated focal left ventricular hypertrophy limited to the apex, and speckle-tracking imaging showed reduced apical strain, findings consistent with apical hypertrophic cardiomyopathy (HCM). Risk assessment for sudden cardiac death was low. A previous invasive coronary artery angiography reported normal epicardial coronary arteries. The patient was started on carvedilol 6.25 mg orally twice daily, with resolution of the chest pain and, so far, a generally optimal quality of life after four months of follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.